Gyros AB
Gyros AB
Blog Post
  • Singlicate Gyrolab immunoassays prove their worth (again) In a previous post, ‘How to get it right first time’, we looked at the reliability and reproducibility of Gyrolab™ assays that lead to the idea of running singlicates instead of duplicates (Clark et al, 2016). This publication inspired Hao Jiang and colleagues in a group based at Bristol-Myers Squibb in Princeton, USA to apply Gyrolab t...

Gyros AB
Gyros AB
Blog Post
  • Guidance with immunoassays from initial assay design to final validation The drive to achieve regulatory approval of protein-based drugs quickly and efficiently demands methods that can deliver reliable data to support studies in pharmacokinetics, toxicokinetics, pharmacodynamics, biomarker analysis, and immunogenicity. This need has powered the development of a wide and somewhat perplexing ra...

Gyros AB
Gyros AB
Blog Post
  • The extreme reliability of Gyrolab assays Whatever your needs in immunoassays, you will almost certainly appreciate an assay that consistently delivers high precision and accuracy. Scientists at Pfizer have reported a retrospective study of pharmacokinetics (PK) data that highlights the reliability of Gyrolab assays.

Gyros AB
Gyros AB
Blog Post
  • Immunoassays support research by coping with a difficult matrix A number of serious eye diseases, such as neovascular age-related macular degeneration (AMD) and diabetic macular edema, involve increase in the leakage of blood vessels in the eye. This is caused by vascular endothelial growth factor (VEGF) and while such diseases can be treated with protein drugs that neutralize VEGF, the drugs ...

Gyros AB
Gyros AB
Blog Post
  • Gyrolab xP workstation generates high quality data faster As the pace of drug development increases, so does the demand on rapid and efficient generation of bioanalytical data in a regulated setting. In testing six ligand-binding assays on Gyrolab™ xP workstation, Rong Liu and her colleagues at Bristol-Myers Squibb have found that the system delivers the performance they need. This included hi...

Gyros AB
Gyros AB
Blog Post
  • Rapid in-solution equilibrium approach to KD determination of biotherapeutic drug candidates  During our latest webinar, Johan Engström, Senior Scientist at Gyros Protein Technolgies gave a short introduction to Gyrolab technology and how you to set up and evaluate classical in-solution equilibrium experiments for determination of sub-nanomolar KD’s and active concentrations of interactants. J...

Gyros AB
Gyros AB
Blog Post
  • How Design of Experiments (DOE) boosts productivity Bioanalytical laboratories often need to quickly develop robust immunoassays to support studies with tight timelines. Immunoassay performance is governed by many factors, such as reagent concentrations and sample dilution, and the classic experimental approach to improving assay performance involves changing one factor at a time. This approa...

Gyros AB
Gyros AB
Blog Post
  • A generic detection reagent makes all the difference Pharmacokinetic (PK) studies of therapeutic proteins in early preclinical development demand great flexibility in bioanalytical methods. This is a real challenge during lead candidate selection when, for example, limited amounts of specific reagents must be labeled for immunoassays. Gregor Jordan and his colleagues at the Pharma Research & E...

Gyros AB
Gyros AB
Blog Post
  • Gyrolab system delivers Determining the immunogenic potential of a therapeutic antibody is a regulatory requirement during clinical development since anti-drug antibodies (ADA) can cause undesirable effects, ranging from loss of drug exposure and efficacy to serious adverse events. Justine Brose and her colleagues at Novimmune SA, Geneva, Switzerland evaluated four platforms to determine which...

Gyros AB
Gyros AB
Blog Post
  • Gyros’ technology overcomes matrix effects in a Phase III PK assay It is not unusual for a pharmacokinetics assay used early on in a study proves to lack the robustness needed to see the drug candidate through to more advanced clinical studies. A team at Genentech experienced just that and they solved the problem by transferring their ELISA to the Gyrolab platform.

Gyros AB
Gyros AB
Blog Post
  • Singlicate Gyrolab immunoassays prove their worth (again) In a previous post, ‘How to get it right first time’, we looked at the reliability and reproducibility of Gyrolab™ assays that lead to the idea of running singlicates instead of duplicates (Clark et al, 2016). This publication inspired Hao Jiang and colleagues in a group based at Bristol-Myers Squibb in Princeton, USA to apply ...

Gyros AB
Gyros AB
Blog Post
  • Guidance with immunoassays from initial assay design to final validation The drive to achieve regulatory approval of protein-based drugs quickly and efficiently demands methods that can deliver reliable data to support studies in pharmacokinetics, toxicokinetics, pharmacodynamics, biomarker analysis, and immunogenicity. This need has powered the development of a wide and somewhat perp...

Gyros AB
Gyros AB
Blog Post
  • The extreme reliability of Gyrolab assays Whatever your needs in immunoassays, you will almost certainly appreciate an assay that consistently delivers high precision and accuracy. Scientists at Pfizer have reported a retrospective study of pharmacokinetics (PK) data that highlights the reliability of Gyrolab assays.

Gyros AB
Gyros AB
Blog Post
  • Immunoassays support research by coping with a difficult matrix A number of serious eye diseases, such as neovascular age-related macular degeneration (AMD) and diabetic macular edema, involve increase in the leakage of blood vessels in the eye. This is caused by vascular endothelial growth factor (VEGF) and while such diseases can be treated with protein drugs that neutralize VEGF, t...

Gyros AB
Gyros AB
Blog Post
  • Gyrolab xP workstation generates high quality data faster As the pace of drug development increases, so does the demand on rapid and efficient generation of bioanalytical data in a regulated setting. In testing six ligand-binding assays on Gyrolab™ xP workstation, Rong Liu and her colleagues at Bristol-Myers Squibb have found that the system delivers the performance they need. This in...

Gyros AB
Gyros AB
Blog Post
  • Rapid in-solution equilibrium approach to KD determination of biotherapeutic drug candidates  During our latest webinar, Johan Engström, Senior Scientist at Gyros Protein Technolgies gave a short introduction to Gyrolab technology and how you to set up and evaluate classical in-solution equilibrium experiments for determination of sub-nanomolar KD’s and active concentrations of intera...

Gyros AB
Gyros AB
Blog Post
  • How Design of Experiments (DOE) boosts productivity   Bioanalytical laboratories often need to quickly develop robust immunoassays to support studies with tight timelines. Immunoassay performance is governed by many factors, such as reagent concentrations and sample dilution, and the classic experimental approach to improving assay performance involves changing one factor at a time. ...

Gyros AB
Gyros AB
Blog Post

Out-Market Your Competitors?

Get complete competitive insights on over 2.2 million companies to drive your marketing strategy.

Create Free Account Log in

By signing up, you agree to the Terms of Service and Privacy Policy.

Out-Market Your Competitors

Get complete competitive insights on over 2.2 million companies to drive your marketing strategy.

Create Free Account

Already a user?  Log in

By signing up, you agree to the Terms of Service and Privacy Policy.